Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details Narrative)

Subsequent Events (Details Narrative) - USD ($)					1 Months Ended	9 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Nov. 02, 2019	Oct. 31, 2019	Oct. 16, 2019	Jul. 15, 2019	Oct. 31, 2019	Sep. 30, 2019	Dec. 31, 2018
Subsequent Event [Line Items]
Excess consideration note						$ 6,822,000
BioPharma Acquisition [Member]
Subsequent Event [Line Items]
Business combination consideration amount				$ 20,651,000
Security Purchase Agreement [Member]
Subsequent Event [Line Items]
Business combination consideration amount						$ 23,500,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Reverse stock split, description	effect a reverse stock split of common stock, at a ratio in the range from one-for-five to one-for-fifteen
Subsequent Event [Member] \| BioPharma Acquisition [Member]
Subsequent Event [Line Items]
Business combination consideration amount		$ 7,692,300
Payment to acquire subordinated seller note		6,024,000
Business combination indemnification holdback		735,000
Accounts receivable		152,858			$ 152,858
Business combination closing net worth adjustment		775,000
Pre closing liabilities		317,628			317,628
Unbilled accounts receivable		289,000			289,000
Excess consideration note		$ 23,674			23,674
Subsequent Event [Member] \| Revolving Line of Credit [Member]
Subsequent Event [Line Items]
Payment of line of credit					$ 3,750
Subsequent Event [Member] \| Security Purchase Agreement [Member] \| 130 Newly Created Series A-1 Preferred Stock [Member]
Subsequent Event [Line Items]
Business combination consideration amount			$ 13,000,000
Subsequent Event [Member] \| Nasdaq Notification [Member]
Subsequent Event [Line Items]
Nasdaq notification decsription		(i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other applicable initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and (ii) the Company providing written notice to Nasdaq of its intent to cure the deficiency during this second compliance period by effecting a reverse stock split, if necessary. If at any time during this second, 180-day period the closing bid price of the Company's Common Stock is at least $1.00 per share for at least a minimum of 10 consecutive business days, the Staff will provide written confirmation of compliance.